Disease Overview：Membranoproliferative glomerulonephritis（MPGN）
Membranoproliferative glomerulonephritis (MPGN) is a rare, immune-mediated kidney disorder characterized by structural changes in the glomeruli—including mesangial hypercellularity, basement membrane thickening, and double-contour formation (“tram-tracking”)—leading to progressive proteinuria, hematuria, hypertension, and eventual decline in glomerular filtration rate. Historically classified into three subtypes (I, II [dense deposit disease], and III), MPGN is now redefined based on underlying pathogenic mechanisms: immune-complex–mediated or complement-driven (e.g., C3 glomerulopathy). Diagnosis relies on renal biopsy with light microscopy, immunofluorescence, and electron microscopy, often supplemented by serum complement profiling (C3, C4, factor H/B, properdin) and genetic testing. Management is individualized and may include corticosteroids, cyclophosphamide, mycophenolate m newer complement inhibitors (e.g., eculizumab, ravulizumab) in select cases. Prognosis varies widely; up to 50% of patients progress to end-stage kidney disease within 10–15 years without effective intervention.
ChinaGN management: leading nephrology centers—such as Peking University First Hospital and Shanghai Renji Hospital—host nationally recognized MPGN referral programs with deep expertise in complement pathway diagnostics and targeted immunomodulation. Advanced capabilities include next-generation complement genetic sequencing, real-time monitoring of soluble C5b-9, and access to FDA- and Nics at approximately 40–60% lower cost than in the US or EU. Over 200 documented international cases demonstrate stable remission and preserved eGFR at 3-year follow-up under protocol-driven care. As a dedicated medical tourism agency, we facilitate seamless access to these resources—coordinating biopsy interpretation, multidisciplinary consultations, visa support, and accommodation—while providing itemized, upfront pricing and continuous clinical advocacy throughout treatment.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Membranoproliferative Glomerulonephritis (MPGN)
Non-Surgical / Conservative / Medication-Based Management
*Target Criteria:* Early-stage MPGN (eGFR ≥60 mL/min/1.73m²), minimal proteinuria (<1 g/day), stable renal function, no crescents on biopsy.
- •First-line immunosuppression (Rituximab-based):
- Prednisone taper (60 mg/day × 4 w → 5 mg/day × 12 w): $45 - Monitoring labs (monthly CBC, LFTs, IgG, CD19+ B-cell count): $120–$180 per cycle
- •ACEi/ARB + SGLT2 inhibitor (standard supportive care):
- •Baseline & surveillance diagnostics:
- Complement panel (C3, C4, CH50, C3NeF, anti-FH Ab): $260–$340 - 24-hr urine protein, serum creatinine, eGFR, albumin: $75 per visit
Surgical / Procedural / Interventional Options
*Eligibility Criteria:* Rapidly progressive MPGN (eGFR decline >30% in 3 months), crescentic glomeruli (>25%), or refractory nephrotic syndrome unresponsive to 6 months of immunosuppression.
- •Plasma exchange (PLEX) – 14-session course (qod × 2 w):
- Pre-op workup (coagulation panel, blood type/crossmatch, vascular access assessment): $190
- •Renal transplantation (for ESRD):
- Transplant surgery + 7-day inpatient stay: $14,200–$17,600 - Induction (Basiliximab × 2 doses) + 1-year maintenance (Tacrolimus + MMF): $2,900–$3,500
Special / Complex Condition Management
- •C3 Glomerulopathy subtype with FH mutation: Eculizumab (off-label, 900 mg IV q2w × 26 w): $48,500–$52,300
- •Post-transplant MPGN recurrence: High-dose IVIG (2 g/kg × 2 doses) + PLEX: $3,800–$4,400
- •Severe thrombotic microangiopathy overlap: Caplacizumab (10 mg SC daily × 30 d): $12,700–$13,900
Quick Selection Guide
- •<40 years, low budget, mild disease (proteinuria <0.5 g/day, eGFR >85): ACEi/ARB + SGLT2i + close monitoring ($285–$465/year)
- •40–65 years, moderate severity (nephrotic-range proteinuria, eGFR 45–60): Rituximab + prednisone + complement testing ($2,300–$2,900 initial year)
- •>65 years or with diabetes/CVD: Avoid aggressive immunosuppression; prioritize BP control, SGLT2i, and PLEX only if rapidly progressive ($1,600–$2,000 for urgent PLEX course)
- •ESRD or transplant-eligible: Prioritize transplant over long-term dialysis (lifetime dialysis cost: $78,000–$92,000 vs. transplant: $18,000–$22,000 upfront + $3,500/year maintenance)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Membranoproliferative glomerulonephritis Medical Vacation Packages
Curated transparent all-inclusive packages combining Membranoproliferative glomerulonephritis treatment with China top medical destinations:
